Christopher D Lascola

US Patent:

20090088578, Apr 2, 2009

Filed:

Jan 22, 2008

Appl. No.:

12/017608

Inventors:

Christopher D. Lascola - Durham NC, US
Allen W. Song - Chapel Hill NC, US
Timothy A. Haystead - Chapel Hill NC, US

International Classification:

A61K 49/10
C07D 209/04
A61B 5/055

US Classification:

548490, 424 93, 600420

Abstract:

Imaging agents for magnetic resonance imaging are disclosed. Also disclosed are methods of non-invasively generating a visible image of a target tissue. In some embodiments, the discloses methods include the steps of (a) providing a contrast enhancement agent comprising a small molecule that binds to a biomolecule present in the target tissue; (b) introducing the contrast enhancement agent into the target tissue; and (c) scanning the target tissue using magnetic resonance imaging, whereby a visible image of the target tissue is non-invasively generated. Further discloses are methods for monitoring a response to a therapy, methods for selecting a therapy for a subject, methods for delineating a boundary between a diseased cell and a non-diseased cell in a tissue, and methods for assessing the degree to which a target tissue has been removed from a subject.

US Patent:

20210353780, Nov 18, 2021

Filed:

Jul 28, 2021

Appl. No.:

17/443863

Inventors:

- Durham NC, US
Christopher David Lascola - Durham NC, US

International Classification:

A61K 49/06
A61K 49/10
A61B 5/00
A61B 5/055
A61K 9/00
A61K 9/08
A61K 47/02
A61K 47/26

Abstract:

A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.

US Patent:

20200297873, Sep 24, 2020

Filed:

Jun 4, 2020

Appl. No.:

16/946056

Inventors:

- Durham NC, US
Christopher David Lascola - Durham NC, US

International Classification:

A61K 49/06
A61K 49/10
A61B 5/00
A61B 5/055
A61K 9/00
A61K 9/08
A61K 47/02
A61K 47/26

Abstract:

Ascorbate or a pharmaceutically acceptable salt thereof is described for use in carrying out a method, or for the preparation of a medicament for carrying out a method, of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject. The method is carried out by parenterally administering ascorbate or a pharmaceutically acceptable salt thereof to the subject in an MRI image-enhancing amount; and then generating, by MRI of the subject, an image of the body or body region. The ascorbate or pharmaceutically acceptable salt thereof enhances the MRI image.

US Patent:

20190231907, Aug 1, 2019

Filed:

Apr 3, 2019

Appl. No.:

16/373803

Inventors:

- Durham NC, US
Christopher David Lascola - Durham NC, US

International Classification:

A61K 49/10
A61K 47/54
A61K 49/08
A61P 35/00
A61K 31/675
A61K 31/663
A61K 9/00

Abstract:

Provided herein are magnetic resonance imaging (MRI) contrast agents comprising a compound having a structure represented by: Y—X—Z, wherein, X is: Fe(III) or Mn(II), and Y and Z are each independently selected from pyrophosphate and bisphosphonate (e.g., 1-hydroxybisphosphonate), or a pharmaceutically acceptable hydrate and/or salt thereof. Methods of use of the MRI contrast agent are also provided.

US Patent:

20190216954, Jul 18, 2019

Filed:

Mar 27, 2019

Appl. No.:

16/365939

Inventors:

- Durham NC, US
Christopher David Lascola - Durham NC, US

International Classification:

A61K 49/06
A61K 47/26
A61K 47/02
A61K 9/08
A61K 49/10
A61B 5/055
A61B 5/00
A61K 9/00

Abstract:

A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.

US Patent:

20190111160, Apr 18, 2019

Filed:

Oct 26, 2016

Appl. No.:

16/095076

Inventors:

- Durham NC, US
Christopher David Lascola - Durham NC, US

International Classification:

A61K 49/10
A61K 31/675
A61K 31/663
A61K 9/00
A61P 35/00

Abstract:

Provided herein is a compound useful as a magnetic resonance imaging (MRI) contrast agent and a therapeutic agent, said compound having a structure represented by: Y—X—Z wherein, X is Mn(II), and Y and Z are each independently a bisphosphonate coupled to one or more therapeutic agents. Methods of use of the compound for MRI imaging and treatment for cancer or a microbial infection are also provided.

US Patent:

20190031661, Jan 31, 2019

Filed:

Jun 5, 2018

Appl. No.:

16/000077

Inventors:

- Durham NC, US
Philip Floyd Hughes - Chapel Hill NC, US
Christopher D. Lascola - Durham NC, US

International Classification:

C07D 473/34
G01N 33/574
C07D 231/54
G01N 33/569
C07D 405/14
C07D 493/10
C07D 473/24
C07D 487/04
C07D 413/12

Abstract:

Described herein are compounds that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. The compounds may include detection moieties such as fluorophores that may allow for selective detection of Hsp90 in a sample.

US Patent:

20180071410, Mar 15, 2018

Filed:

Nov 14, 2017

Appl. No.:

15/812013

Inventors:

- Durham NC, US
Christopher David Lascola - Durham NC, US

International Classification:

A61K 49/06
A61B 5/00
A61B 5/055

Abstract:

Ascorbate or a pharmaceutically acceptable salt thereof is described for use in carrying out a method, or for the preparation of a medicament for carrying out a method, of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject. The method is carried out by parenterally administering ascorbate or a pharmaceutically acceptable salt thereof to the subject in an MRI image-enhancing amount; and then generating, by MRI of the subject, an image of the body or body region. The ascorbate or pharmaceutically acceptable salt thereof enhances the MRI image.